ReviewAdvanced drug delivery reviews2018
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.
Review in Advanced drug delivery reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed.
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Target-Triggered Self-Assembly of Peptides with Silver Nanoparticles for Electrochemical Biosensing.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Size-shrinking nanoparticles with high drug-protein payload for efficient, non-invasive treatment of corneal neovascularization.Journal of nanobiotechnology · 2026Article
- A receptor-Fc based SFV replicon Trim-Away platform for targeted viral protein degradation.Virology journal · 2026Article
- Therapeutic peptides and proteins: Status and developments in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Peripheral Blood Mononuclear Cell Oxygen Consumption and Systemic Bioenergetics in Glaucoma Management.International journal of molecular sciences · 2026Review
- Chitosan-Coated Silver-Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis.Investigative ophthalmology & visual science · 2026Article
- Development of Autologous Serum Ocular Insert for Chronic Dry Eye Disease.Pharmaceutics · 2026Article
- Continuous Suppression of Pathological Retinal and Choroidal Neovascularization in Cynomolgus Monkeys via Noninvasive Ophthalmic Delivery of a Novel Anti-VEGFA Nanobody and Proprietary Penetratin Analog Formulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases.Current drug delivery · 2026Review
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- Characterization of hydrolase activity in ocular tissues of humans and preclinical species.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.Cellular & molecular immunology · 2025Article
- Comparative transcriptomic profiling of drug-metabolizing enzymes and drug transporters in rabbit ocular subtissues, liver, and duodenum.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Biodegradable Contact Lenses for Targeted Ocular Drug Delivery: Recent Advances, Clinical Applications, and Translational Perspectives.Molecules (Basel, Switzerland) · 2025Review
- Hybrid NIR-responsive liposome/hydrogel platform mediating chemo-photothermal therapy of retinoblastoma enhanced by quercetin as an adjuvant.Theranostics · 2025Article
- Expanding Arsenal against Ocular Diseases through Nanoemulsion: Success So Far and the Road Ahead.Current drug delivery · 2025Review
- Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.International journal of nanomedicine · 2025Review
- Mesenchymal Stem Cell-Derived Exosomes for Ocular Diseases: Therapeutic Mechanisms and Clinical Perspectives.International journal of nanomedicine · 2025Review
- Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases.Nature biomedical engineering · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The impact of proteins and peptides on the treatment of various conditions including ocular diseases over the past few decades has been advanced by substantial breakthroughs in structural biochemistry, genetic engineering, formulation and delivery approaches. Formulation and delivery of proteins and peptides, such as monoclonal antibodies, aptamers, recombinant proteins and peptides to ocular tissues poses significant challenges owing to their large size, poor permeation and susceptibility to degradation. A wide range of advanced drug delivery systems including polymeric controlled release systems, cell-based delivery and nanowafers are being exploited to overcome the challenges of frequent administration to ocular tissues. The next generation systems integrated with new delivery technologies are anticipated to generate improved efficacy and safety through the expansion of the therapeutic target space. This review will highlight recent advances in formulation and delivery strategies of protein and peptide based biopharmaceuticals. We will also describe the current state of proteins and peptides based ocular therapy and future therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.